Fasciculoventricular Pathway in a Young Athlete-A Case Report.

Clin J Sport MedJan 14, 2026 (epub)

Rita Amador, Joana Certo Pereira, Miguel Mata et al.

✦ AI-curated · Sources linked

Case in brief

A 12-year-old male athlete was referred for asymptomatic pre-excitation found on a routine electrocardiogram. Pre-excitation persisted during exercise testing up to maximum heart rate. Electrophysiologic study identified a fasciculoventricular pathway (FVP), with no inducible arrhythmia. Ablation was not attempted, and he was discharged with unrestricted return-to-play authorization.

What made this case unusual

Persistent pre-excitation at maximum heart rate was evaluated electrophysiologically and attributed to an FVP rather than a more common accessory pathway.

Diagnostic / clinical pearl

In an asymptomatic patient with pre-excitation, electrophysiologic evaluation can identify an FVP and help avoid unnecessary ablation or exercise restriction.

Why it matters

FVPs are not substrates for re-entrant tachycardia and are not associated with sudden death, according to the report.

Source

Published in Clin J Sport Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.